Moderna’s Covid-19 vaccine shows 94.5% efficacy in Phase 3 data analysis
Moderna intends to seek the US FDA’s Emergency Use Authorisation (EUA) based on the interim data analysis of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Nov 20
Moderna intends to seek the US FDA’s Emergency Use Authorisation (EUA) based on the interim data analysis of…
12 Nov 20
The efficacy of the Sputnik V vaccine is calculated based on 20 confirmed Covid-19 cases, who received either…
11 Nov 20
Treatment using tezepelumab in the NAVIGATOR Phase 3 clinical trial was well tolerated in patients with severe asthma
10 Nov 20
The vaccine candidate was more than 90% effective in preventing Covid-19 in participants without prior SARS-CoV-2 infection
04 Nov 20
Vupanorsen is an investigational antisense therapy, discovered by Ionis Pharmaceuticals and co-developed by Ionis and its subsidiary Akcea…
26 Oct 20
Finerenone is an investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, which prevents kidney and cardiovascular damage
26 Oct 20
Jardiance reduced risk of cardiovascular death and hospitalisation for heart failure, along with serious adverse kidney outcomes in…
12 Oct 20
Zeposia met both primary and secondary efficacy endpoints in the clinical trial and showed statistically significant improvements
08 Oct 20
The data from interim post-authorisation study showed an overall performance of 93.3% sensitivity and 98.4% specificity for ID…
08 Oct 20
Phase 3 AFFINE study is an open-label, multicentre, single-arm study, designed to evaluate the efficacy and safety of…